Please assess the completion status of the following clinical trial:

Trial Title: A Study for Ureter Visualization, Using ASP5354 in Subjects Undergoing Laparoscopic/Minimally Invasive Colorectal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is scheduled to undergo laparoscopic/minimally invasive colorectal surgery.~* Subject will need visualization of the ureter(s).~* Female subject is not pregnant and at least 1 of the following conditions apply:~  * Not a woman of childbearing potential (WOCBP)~ * WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 30 days after final study treatment administration.~* Female subject must agree not to breastfeed starting at screening and throughout the study period.~* Female subject must not donate ova starting at first dose of investigational product (IP) and throughout the study period and for 30 days after final study treatment administration.~* Male subject with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 30 days after final study treatment administration.~* Male subject must not donate sperm during the treatment period and for 30 days after final study treatment administration.~* Male subject with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 30 days after final study treatment administration.~* Subject agrees not to participate in another interventional study while participating in the present study.~* Subjects enrolled after optimal dose determination:~Subject has any of the following values at screening:~* Body mass index \> 25~* Estimated glomerular filtration rate (eGFR) ≥ 15 mL/min/1.73 m\^2 and \< 60. Subjects with an eGFR ≥ 60 mL/min/1.73 m\^2 may be considered after discussion with the medical monitor.~Exclusion Criteria:~* Subject is anticipated to require ureteral stenting during surgery.~* Subject has a history of known retroperitoneal fibrosis.~* Subject has an active urinary tract infection.~* Subject has received any investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening.~* Subject has any condition that makes the subject unsuitable for study participation.~* Subject has a known or suspected hypersensitivity to ASP5354, indocyanine green (ICG) or any components of the formulation used.~* Subject has had previous exposure to ASP5354.~* Subject has moderate to severe cardiac disease that limits daily functioning (New York Heart Association Class III-IV) or other medical conditions that the investigator feels would impact safety or study compliance.~* Subject has a mean resting heart rate ≤ 45 bpm or ≥ 115 bpm, mean systolic blood pressure (SBP) ≥ 160 mmHg or mean diastolic blood pressure (DBP) ≥ 100 mmHg on day -1. If the mean blood pressure exceeds the limits above, repeat readings can be taken. Subject who has adequately controlled blood pressure is eligible.~* Subject has a mean corrected QT interval (Triplicate electrocardiogram \[ECG\]) using Fridericia's formula (QTcF) \> 430 msec (for male subjects) and \> 450 msec (for female subjects) on day -1. If the mean QTcF exceeds the limits above, the mean of 1 additional triplicate ECG may be taken.~* Subject has any of the following screening laboratory values:~  * Hemoglobin ≤ 9 g/dL~ * Absolute neutrophil count ≤ 1500/µL~ * Platelet count ≤ 100000/µL~ * eGFR \< 60 mL/min/1.73 m\^2 (Not applicable to subjects enrolled after optimal dose determination.)~ * Serum bilirubin ≥ 2 × upper limit of normal (ULN)~ * Aspartate aminotransferase (AST) or serum glutamic oxaloacetic transaminase ≥ 2.5 × ULN~ * Alanine aminotransferase (ALT) or serum glutamic pyruvic transaminase ≥ 2.5 × ULN~* Subject has taken ICG or other near-infrared fluorescence (NIR)-F imaging agents within 48 hours prior to study treatment administration.~* Subject has taken diuretics or inhibitors of renal transporters defined by Food and Drug Administration (FDA) within 48 hours prior to study treatment administration.~* Subject has used any illicit drugs, unless legally prescribed and is not being abused (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and opiates) within 1 month prior to day -1.~* Subject has a history of alcohol abuse. Subject should not have consumed any alcohol within 48 hours of surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pudexacianinium chloride - Dose Level A (Type: EXPERIMENTAL): Participants received single dose of pudexacianinium chloride at dose level A by intravenous (IV) bolus infusion on day 1 once the surgical area of interest is in view.
- Pudexacianinium chloride - Dose Level B (Type: EXPERIMENTAL): Participants received single dose of pudexacianinium chloride at dose level B by IV bolus infusion on day 1 once the surgical area of interest is in view.
- Pudexacianinium chloride - Dose Level C (Type: EXPERIMENTAL): Participants received single dose of pudexacianinium chloride at dose level C by IV bolus infusion on day 1 once the surgical area of interest is in view.
- Pudexacianinium chloride - Dose Level B - Dose Expansion (Type: EXPERIMENTAL): Participants who were enrolled in the dose expansion group received single dose of pudexacianinium chloride at dose level B by IV bolus infusion on day 1 once the surgical area of interest is in view.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete